ClinicalTrials.gg
DrugBiologicalRead study by study

Dostarlimab clinical trials

Also written TSR-042, Jemperli and ANB011.

studies test it
77
open now
31
in phase 3
13
first study started
2016
ClinicalTrials.gov finds 108 studies for dostarlimab. How that becomes 77 here

Every study that search finds has been read, to see whether and how it gives dostarlimab. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 108Found by its intervention search · See all 108 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 95 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. 108Give dostarlimab to participants
  3. −5Observe patients on it, or give it outside a trial
  4. −26Give it beside what is tested
  5. 77Test it: the count on this site

Get an email when these change. Save the dostarlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Apr 2021 · JEMPERLI · BLA 761174 (FDA, Drugs@FDA)
European Union
21 Apr 2021 · Jemperli · EMEA/H/C/005204 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Dostarlimab
57
Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer
4
Dostarlimab-gxly
3

Brand

Jemperli
9

Development codes

TSR-042
24
ANB011
4
GSK4057190
3
GSK4057190A
2
WBP-285
1

Studies by the year they started

77 studies that test it; most in 2023 (12)

Studies that test dostarlimab, by start year
YearStudies
20161
20173
20183
20199
202011
202111
20222
202312
202410
202510
20265

By phase

A phase 1/2 study counts in both.

Phase 1
12
Phase 2
57
Phase 3
13
Phase 4
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 26 · Other 51

GlaxoSmithKline (17) · Tesaro, Inc. (8) · M.D. Anderson Cancer Center (3) · ARCAGY/ GINECO GROUP (2) · Grupo Español de Investigación en Cáncer de Ovario (2) · Massachusetts General Hospital (2) · Memorial Sloan Kettering Cancer Center (2) · University of Oklahoma (1)

Often tested with

Tested in the same studies.

Niraparib (20) · Bevacizumab (3) · Carboplatin (3) · Paclitaxel (3) · Cobolimab (3) · Atezolizumab (3) · Pembrolizumab (2) · Carboplatin/Paclitaxel Regimen (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 8 most studied

New when their studies opened, with dostarlimab beside them; studies of each.

Reaching primary completion within a year · 17, 2 in phase 3

Studies that test dostarlimab, phase 3 first.

Studies

Open first, then newest update. How each study uses dostarlimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 77

See all 77 studies that test dostarlimab →

Behind its US label · 4 — the studies the FDA label of JEMPERLI describes

From the Clinical Studies section of JEMPERLI (2026-10), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 20 — no other medicine in its arm
Tested with established drugs · 19 — they are given beside it
Tested in a combination · 38 — another drug in the study is under test too

Showing 20 of 38. See all 38 →

Beside an established treatment under test · 2 — an approved drug, surgery or radiation is what the study tests

Tested with dostarlimab: Radiation 2 · niraparib 1

Beside a new treatment under test · 20 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with dostarlimab: belrestotug 6 · nelistotug 6 · cobolimab 4 · risvutatug rezetecan 3 · remzistotug 2 · feladilimab 2 · roginolisib 1 · inupadenant 1

Beside supportive care · 1 — a supportive treatment or test is studied
One option of several · 3 — a test or a strategy chooses among drugs
Observed · 5 — patients on it are followed, or it is given outside a trial

Codes

What other systems call dostarlimab · ClinicalTrials.gg INT001720

  • MeSH (NLM) C000719628dostarlimabOne source ClinicalTrials.gov
  • UNII (FDA) P0GVQ9A4S5DOSTARLIMABConfirmed FDA, Wikidata
  • RxNorm 2539967One source FDA
  • Wikidata Q85757472dostarlimabConfirmed FDA, Wikidata
  • NCI Thesaurus C126799DostarlimabOne source FDA
  • DrugBank DB15627One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion